Telix Pharmaceuticals stock (AU000000TLX2): Key FDA decision on horizon

Telix Pharmaceuticals eyes momentum regain ahead of critical FDA decision on radiopharmaceutical pipeline, with Illuccix driving prostate cancer diagnostics revenue.

Telix Pharmaceuticals Ltd, listed on the ASX as TLX, is drawing investor attention ahead of a key FDA decision on its radiopharmaceutical developments. The company's lead product Illuccix, a PSMA-targeted imaging agent for prostate cancer, continues to fuel commercial growth across key markets including the US. This comes as shares traded at $21.09 AUD on July 28, 2025 on the ASX, according to StockInvest.us as of Jul 28, 2025.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Telix Pharmaceuticals Ltd
• Sector/industry: Radiopharmaceuticals / Healthcare
• Headquarters/country: Australia
• Core markets: US, Europe, Japan
• Key revenue drivers: Illuccix diagnostics
• Home exchange/listing venue: ASX (TLX)
• Trading currency: AUD

Telix Pharmaceuticals: core business model

Telix Pharmaceuticals develops and commercializes radiopharmaceuticals for cancer diagnostics and therapy. The company focuses on targeted therapies using alpha and beta particle emitters, with a pipeline spanning prostate, kidney, and brain cancers. Illuccix, approved by the FDA in 2021, remains the cornerstone product, generating revenue from PSMA PET imaging in the US market.

Headquartered in Melbourne, Australia, Telix operates globally with offices in the US, Europe, Japan, and Switzerland. Its business model emphasizes late-stage clinical assets nearing commercialization, positioning it as a leader in theranostics – combining diagnostics and therapeutics.

Main revenue and product drivers for Telix Pharmaceuticals

Illuccix drives the majority of revenue, used in over 200,000 prostate cancer scans annually in the US alone, according to company disclosures via Telix IR as of 2026. The product benefits from strong reimbursement and partnerships with major imaging centers. Pipeline candidates like TLX591 (targeted radiotherapy) and TLX101-CDx (glioblastoma imaging) advance toward approvals.

US exposure is significant, with Illuccix sales ramping post-FDA nod. Telix's strategy targets precision oncology, where radiopharmaceuticals offer advantages over traditional imaging in detecting metastases early.

Industry trends and competitive position

The radiopharmaceutical sector is expanding rapidly, driven by demand for targeted cancer treatments. Global market projections estimate growth to $10 billion by 2030, per sector reports. Telix competes with players like Novartis and Bayer but differentiates via PSMA expertise and a broad pipeline.

In the US, Telix's Illuccix holds a strong position in prostate cancer diagnostics, with expanding adoption amid rising incidence rates.

Why Telix Pharmaceuticals matters for US investors

Telix offers US investors exposure to high-growth radiopharma via ASX listing, with substantial revenue from FDA-approved Illuccix. The US accounts for a major share of sales, tying performance to American healthcare spending and oncology trends. ADR availability enhances accessibility for US portfolios.

Conclusion

Telix Pharmaceuticals stands at an inflection point with upcoming FDA milestones and Illuccix commercialization. Steady revenue growth from US diagnostics underscores its theranostics focus, while pipeline progress signals long-term potential. Investors track regulatory outcomes amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.